Inventiva S.A. American Depository Shares (IVA)
NASDAQ: IVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IVA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $750.78M
- EPS (TTM)
- -$0.62
- Dividend yield
- None
- 52-week range
- 2.82 – 7.29
- Day range
- 3.13 – 3.44
- Volume / Avg
- 3.02M / 2.40M
- Beta
- —
- Shares outstanding
- 239.10M
52-week range
IVA stock today
On Nov 20, IVA ended the session at $3.14, shedding $0.31 (8.99%), versus the S&P 500's 3.70% decline. At this level, IVA sits near the bottom of its 52-week range of $2.82 to $7.29: 56.9% below the high, set on Jan 26, 2026 and 11.3% above the low. IVA is down 32.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 27.0%.
Inventiva S.A. American Depository Shares has posted a net loss over the last twelve months (EPS of -$0.62), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Inventiva S.A. American Depository Shares
Company profileInventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Andrew Obenshain
- Headquarters
- Daix
- Employees
- 87
- IPO year
- 2020
- Website
- inventivapharma.com
Financial highlights
Full financialsInventiva S.A. American Depository Shares reported a net loss of $49.6 million.
| Fiscal year | FY 2021 |
|---|---|
| Revenue | — |
| Growth | — |
| Net income | $-49.63M |
| EPS (diluted) | — |
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$14.42+359.24%
- Strong buy 1
- Buy 12
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
IVA news
All IVA newsInventiva S.A. American Depository Shares peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ARDXArdelyx Inc. | 2.99 | -2.29% | $751.60M | vs IVA |
| RIGLRigel Pharmaceuticals Inc. | 40.09 | -2.67% | $754.89M | vs IVA |
| OBXObsidian Therapeutics Inc. | 12.00 | -1.23% | $741.29M | vs IVA |
| ORICOric Pharmaceuticals Inc. | 7.36 | -4.42% | $764.94M | vs IVA |
| COLLCollegium Pharmaceutical Inc. | 24.72 | -1.94% | $768.18M | vs IVA |
| IRWDIronwood Pharmaceuticals Inc. Class A | 4.70 | -0.21% | $778.09M | vs IVA |
| SNDXSyndax Pharmaceuticals Inc. | 8.72 | -4.49% | $785.05M | vs IVA |
| VSTMVerastem Inc. | 6.33 | -7.73% | $797.67M | vs IVA |
Indexes, lists and sector
Inventiva S.A. American Depository Shares stock FAQ
What is Inventiva S.A. American Depository Shares's stock price today?
IVA last traded at $3.14 as of Nov 20, 4:00 PM EST, down 8.99% on the day. Prices are delayed at least 15 minutes.
Who is Inventiva S.A. American Depository Shares's CEO?
Mr. Andrew Obenshain is the chief executive officer of Inventiva S.A. American Depository Shares, which has about 87 employees.
What is the IVA 52-week high?
The 52-week high for IVA is $7.29 and the 52-week low is $2.82. The stock is currently 56.9% below its high.